
|Videos|December 16, 2022
Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial
Author(s)Neal Shore, MD, FACS
Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5



















